trending Market Intelligence /marketintelligence/en/news-insights/trending/ACaxHOZ3yWE-RBa5fK-kVw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Novo Nordisk wins FDA panel endorsement for diabetes drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novo Nordisk wins FDA panel endorsement for diabetes drug

A U.S. Food and Drug Administration advisory panel recommended approving the Novo Nordisk A/S diabetes drug semaglutide.

The Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0, with one abstention, in favor of the approval.

Data showed that semaglutide was linked with an initial worsening of diabetic retinopathy but the panelists noted that this risk was offset by the benefit of reducing blood sugar overall, Reuters reported Oct. 18.

Diabetic retinopathy is a diabetes complication that affects the eyes.

The agency is not required to follow the recommendations of its advisers but often does.